Edward L C Pritchett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edward L C Pritchett has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Charles Kerr
1 shared publicationGerald Fava
1 shared publicationKarl Undesser
1 shared publicationMark Carlson
1 shared publicationPeter Kowey
1 shared publicationRichard L Page
1 shared publication
Latest Publications
- 1 May 2006
- Published by Elsevier in American Heart Journal
- Vol. 151 (5) , 1043-1049
Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm
- 1 May 2006
- Published by Elsevier in American Heart Journal
- Vol. 151 (5) , 1043-1049
Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm
- 31 July 2004
- Published by Elsevier in Heart Rhythm
- Vol. 1 (2) , 36-40
Symptomatic arrhythmia recurrence as an outcome in clinical trials of antiarrhythmic drug therapy
- 31 July 2004
- Published by Elsevier in Heart Rhythm
- Vol. 1 (2) , 36-40
Symptomatic arrhythmia recurrence as an outcome in clinical trials of antiarrhythmic drug therapy
- 1 October 2003
- Published by Elsevier in The American Journal of Cardiology
- Vol. 92 (8) , 941-946
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation
- 1 October 2003
- Published by Elsevier in The American Journal of Cardiology
- Vol. 92 (8) , 941-946
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation
- 1 September 2003
- Published by Springer Nature in Cardiac Electrophysiology Review
- Vol. 7 (3) , 215-219
Azimilide for Atrial Fibrillation: Clinical Trial Results and Implications
Azimilide dihydrochloride (or azimilide) is a class III antiarrhythmic drug currently under investigation that has been tested in atrial fibrillation in four randomized, placebo-controlled clinical trials to assess efficacy and dose range. These investigational trials showed that doses of azimilide 100 and 125 mg once daily prolonged the time to symptomatic arrhythmia recurrence in patients with a history of symptomatic atrial fibrillation, atrial flutter or both. Doses of 75 mg or less were not useful in this indication. Safety of azimilide has been examined in several different types of studies. In a large randomized clinical trial of post-infarct patients, azimilide neither increased nor decreased mortality risk. In patients with supraventricular arrhythmias, the most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Infrequent cases of torsade de pointes and severe neutropenia were reported in patients taking azimilide. Azimilide is an investigational antiarrhythmic drug that has shown efficacy in patients with atrial fibrillation.
- 1 September 2003
- Published by Springer Nature in Cardiac Electrophysiology Review
- Vol. 7 (3) , 215-219
Azimilide for Atrial Fibrillation: Clinical Trial Results and Implications
Azimilide dihydrochloride (or azimilide) is a class III antiarrhythmic drug currently under investigation that has been tested in atrial fibrillation in four randomized, placebo-controlled clinical trials to assess efficacy and dose range. These investigational trials showed that doses of azimilide 100 and 125 mg once daily prolonged the time to symptomatic arrhythmia recurrence in patients with a history of symptomatic atrial fibrillation, atrial flutter or both. Doses of 75 mg or less were not useful in this indication. Safety of azimilide has been examined in several different types of studies. In a large randomized clinical trial of post-infarct patients, azimilide neither increased nor decreased mortality risk. In patients with supraventricular arrhythmias, the most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Infrequent cases of torsade de pointes and severe neutropenia were reported in patients taking azimilide. Azimilide is an investigational antiarrhythmic drug that has shown efficacy in patients with atrial fibrillation.
- 1 May 1991
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 49 (5) , 481-487
New drug application strategies for supraventricular arrhythmias
- 1 May 1991
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 49 (5) , 481-487
New drug application strategies for supraventricular arrhythmias